Alzheimer’s disease (AD) is an intractable neurodegenerative disease showing a clinical manifestation with memory loss, cognitive impairment and behavioral dysfunction. The predominant pathological characteristics of AD include neuronal loss, β-amyloid (Aβ) deposition and hyperphosphorylated Tau induced neurofibrillary tangles (NFTs), while considerable studies proved these could be triggered by neuronal death and neuroinflammation. Receptor-interacting protein kinase 1 (RIPK1) is a serine/threonine kinase existed at the cross-point of cell death and inflammatory signaling pathways. Emerging investigations have shed light on RIPK1 for its potential role in AD progression. The present review makes a bird’s eye view on the functions of RIPK1 and mainly focus on the underlying linkages between RIPK1 and AD from comprehensive aspects including neuronal death, Aβ and Tau, inflammasome activation, BBB rupture, AMPK/mTOR, mitochondrial dysfunction and O-glcNAcylation. Moreover, the discovery of RIPK1 inhibitors, ongoing clinical trials along with future RIPK1-targeted therapeutics are also reviewed.

阿尔茨海默病 (Alzheimer's disease, AD) 是一种难治性神经退行性疾病，临床表现为记忆力减退、认知障碍和行为障碍。AD 的主要病理特征包括神经元丢失、β-淀粉样蛋白 (Aβ) 沉积和过度磷酸化 Tau 诱导的神经原纤维缠结 (NFT)，而大量研究证明这些可能由神经元死亡和神经炎症引发。受体相互作用蛋白激酶 1 (RIPK1) 是一种存在于细胞死亡和炎症信号通路交叉点的丝氨酸/苏氨酸激酶。新兴研究揭示了 RIPK1 在 AD 进展中的潜在作用。本综述对 RIPK1 的功能进行了概述，主要从神经元死亡、Aβ 和 Tau、炎性体激活、BBB 破裂、AMPK/mTOR、线粒体功能障碍和 O- glcNA酰化。此外，还回顾了 RIPK1 抑制剂的发现、正在进行的临床试验以及未来的 RIPK1 靶向治疗。